Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MaxCyte, Inc. - Common Stock (NQ:MXCT)

0.9892 -0.0208 (-2.06%)
Delayed Quote Updated: 10:41 AM EDT, Oct 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about MaxCyte, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
MaxCyte (MXCT) Q2 2026 Earnings Call Transcript ↗
Revenue declined 15% year-over-year, but net losses narrowed significantly. 
Via The Motley Fool
Topics Earnings
News headline image
MaxCyte Q2 Earnings Call Highlights ↗
MaxCyte (NASDAQ:MXCT) reported second-quarter 2026 revenue of $7.3 million, down 15% from $8.5 million a year earlier, as lower license revenue, timing of instrument placements and prior-year... 
Via MarketBeat
Topics Earnings
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
MaxCyte (NASDAQ:MXCT) Q1 2026 Results Beat Estimates, Stock Rises on Buyback ↗
Via Chartmill
MaxCyte Inc (NASDAQ:MXCT) Reports Q4 2025 Revenue Miss and Cautious 2026 Outlook ↗
Via Chartmill
News headline image
Earnings Scheduled For November 12, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 5, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 7, 2025 ↗
 
Via Benzinga
News headline image
MaxCyte Q1 Earnings Call Highlights ↗
MaxCyte (NASDAQ:MXCT) reported lower first-quarter revenue compared with the prior year, as management said discontinued SPL programs and inventory management by its largest customer weighed on core... 
Via MarketBeat
Topics Earnings
News headline image
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript ↗
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Insights into MaxCyte's Upcoming Earnings ↗
 
Via Benzinga
News headline image
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday ↗
 
Via Benzinga
News headline image
A Look at MaxCyte's Upcoming Earnings Report ↗
 
Via Benzinga
News headline image
Thursday's session: top gainers and losers ↗
Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are moving on Thursday? ↗
Wondering how the US markets performed in the middle of the day on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
Traders are paying attention to the gapping stocks in Thursday's session. ↗
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
MaxCyte (MXCT) Q2 Revenue Drops 18% ↗
Via The Motley Fool
News headline image
Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
These stocks are moving in today's after hours session ↗
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
News headline image
Earnings Scheduled For March 11, 2025 ↗
 
Via Benzinga
News headline image
MarketBeat Week in Review – 01/20 - 01/24
Stocks surged higher as investors reacted positively to dovish tariff news; next week will be highlighted by the Federal Reserve meeting and some tech earnings 
Via MarketBeat
Topics Economy Government World Trade
News headline image
MaxCyte: Building the Future of Cell and Gene Therapy Innovation
MaxCyte's proprietary Flow Electroporation technology enables companies like Vertex and CRISPR Therapeutics to get FDA approved for their gene-editing therapy. 
Via MarketBeat
News headline image
MXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q2 2024 ↗
MXCT stock results show that MaxCyte beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
MXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q1 2024 ↗
MXCT stock results show that MaxCyte beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket ↗
Shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA) rose sharply in today’s pre-market trading after the company reported a year-over-year increase in FY23 EPS results. 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.